নির্দেশনা

Primary Hypercholesterolemia: Ezetimibe co-administered with statin is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia who are not appropriately controlled with a statin alone. Ezetimibe monotherapy ... Read more Primary Hypercholesterolemia: Ezetimibe co-administered with statin is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia who are not appropriately controlled with a statin alone. Ezetimibe monotherapy is indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia in whom a statin is considered inappropriate or is not tolerated. Prevention of Cardiovascular Events: Ezetimibe is indicated to reduce the risk of cardiovascular events in patients with coronary heart disease (CHD) and a history of acute coronary syndrome (ACS) when added to ongoing statin therapy or initiated concomitantly with a statin. Homozygous Familial Hypercholesterolaemia (HoFH): Ezetimibe co-administered with a statin, is indicated as adjunctive therapy to diet for use in patients with HoFH. Patients may also receive adjunctive treatments (e.g., LDL apheresis). Homozygous Sitosterolemia (Phytosterolemia): Ezetimibe is indicated as adjunctive therapy to diet for use in patients with homozygous familial sitosterolemia.

Composition

ফার্মাকোলজি

Ezetimibe localises at the brush border of the small intestine and inhibits absorption of cholesterol via the sterol transporter, Niemann-Pick C1-Like1 (NPC1L1). This results in decreased delivery of cholesterol to the liver, reduction of hepatic cholesterol stores and increased clearance of cholesterol from the blood.

মাত্রা ও সেবনবিধি

The patient should be on an appropriate lipid lowering diet and should continue on this diet during treatment with Ezetimibe. Adult Dose : The recommended dose is Ezetimibe 10 mg tablet once daily. Ezetimibe can be administered at any time of the day, with or without food. Use in the elderly : No dosage adjustment is required for elderly patients. Pediatric Use - 10 to 17 years: No dosage adjustment is required. The clinical experience in pediatric and adolescent patients is however limited. When Ezetimibe is administered with statin, the dosage instructions for statin, in adolescents should be consulted. Children <10 years: Ezetimibe is not recommended for use in children below age 10 due to insufficient data on safety and efficacy. Use in hepatic impairment : No dosage adjustment is required in patients with mild hepatic insufficiency (Child Pugh score 5 to 6). Treatment with Ezetimibe is not recommended in patients with moderate (Child Pugh score 7 to 9) or severe (Child Pugh score>9) liver dysfunction. Use in renal impairment : No dosage adjustment is required for renally impaired patients

প্রতিনির্দেশনা

Hypersensitivity to any component of this medication. The combination of Ezetimibe with an HMG-CoA reductase inhibitor is contraindicated in patients with active liver disease or unexplained persistent elevations in serum transaminases.

পার্শ্ব প্রতিক্রিয়া

Clinical studies of Ezetimibe (administered alone or with an HMG-CoA reductase inhibitor) demonstrated that Ezetimibe was generally well tolerated. The overall incidence of adverse events reported with Ezetimibe was similar to that reported with placebo, and the discontinuation rate due to adverse events was also similar for Ezetimibe and placebo. The following adverse reactions were observed in patients treated with ezetimibe: Common or very common: Fatigue, gastro-intestinal disturbances, headache, myalgia. Rare: Anaphylaxis, angioedema, arthralgia, hepatitis, hypersensitivity reactions, rash. Very rare: Cholecystitis, cholelithiasis, myopathy, pancreatitis, raised creatine kinase, rhabdomyolysis, thrombocytopenia.

গর্ভাবস্থায় ও স্তন্যদানকালে

Pregnancy : Ezetimibe should be given to pregnant women only if clearly necessary. No clinical data are available on the use of Ezetimibe during pregnancy. Animal studies on the use of ezetimibe in monotherapy have shown no evidence of direct or indirect harmful effects on pregnancy, embryofoetal development, birth or postnatal development. Breast feeding : Ezetimibe should not be used during lactation. Studies on rats have shown that ezetimibe is secreted into breast milk. It is not known if ezetimibe is secreted into human breast milk. Fertility : No clinical data are available. No effects on fertility were observed in non-clinical studies.

সতর্কতা

Concurrent administration of Ezetimibe with a specific HMG-CoA reductase inhibitor should be in accordance with the product labeling for that HMG-CoA reductase inhibitor.

থেরাপিউটিক ক্লাস

Ezetimibe

সংরক্ষণ